Evidence map›Paper›PMID 31028383›Full record

ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2020

Chronic kidney disease, heart failure and neprilysin inhibition.

Richard Haynes, Doreen Zhu, Parminder K Judge, William G Herrington, Philip A Kalra, Colin Baigent

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Role of Neprilysin and Insulin-Degrading Enzyme in the Etiology of Sporadic Alzheimer's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Richard HaynesMedical Research Council Population Health Research Unit, University of Oxford, Headington, Oxford, UK.
Doreen ZhuClinical Trial Service Unit and Epidemiological Studies Unit, Headington, Oxford, UK.
Parminder K JudgeMedical Research Council Population Health Research Unit, University of Oxford, Headington, Oxford, UK.
William G HerringtonMedical Research Council Population Health Research Unit, University of Oxford, Headington, Oxford, UK.
Philip A KalraDepartment of Renal Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, UK.
Colin BaigentMedical Research Council Population Health Research Unit, University of Oxford, Headington, Oxford, UK.
University of Oxford · GBMRC Clinical Trials Unit at UCL · GBSalford Royal NHS Foundation Trust · GB

Funding

Medical Research Council MC_UU_00017/3Medical Research Council MR/R007764/1
6 · The paper itself

Abstract

Patients with chronic kidney disease are at increased risk of cardiovascular disease and this often manifests clinically like heart failure. Conversely, patients with heart failure frequently have reduced kidney function. The links between the kidneys and cardiovascular system are being elucidated, with blood pressure being a key risk factor. Patients with heart failure have benefitted from many trials which have now established a strong evidence based on which to base management. However, patients with advanced kidney disease have often been excluded from these trials. Nevertheless, there is little evidence that the benefits of such treatments are modified by the presence or absence of kidney disease, but more direct evidence among patients with advanced kidney disease is required. Neprilysin inhibition is the most recent treatment to be shown to improve outcomes among patients with heart failure. The UK HARP-III trial assessed whether neprilysin inhibition improved kidney function in the short- to medium-term and its effects on cardiovascular biomarkers. Although no effect (compared to irbesartan control) was found on kidney function, allocation to neprilysin inhibition (sacubitril/valsartan) did reduce cardiac biomarkers more than irbesartan, suggesting that this treatment might improve cardiovascular outcomes in this population. Larger clinical outcomes trials are needed to test this hypothesis.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsClinical Trials as TopicHeart FailureHumansNeprilysinRenal Insufficiency, ChronicAminobutyratesAngiotensin Receptor AntagonistsNeprilysinblood pressurecardiovascularCKDheart failurerenin-angiotensin system

Identifiers

PMID31028383
PMCPMC7139204
OpenAlexW2940903529

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.